6.25
price up icon0.81%   0.05
after-market After Hours: 6.25
loading
Precision Biosciences Inc stock is traded at $6.25, with a volume of 162.52K. It is up +0.81% in the last 24 hours and down -16.33% over the past month. Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
See More
Previous Close:
$6.20
Open:
$6.2
24h Volume:
162.52K
Relative Volume:
0.49
Market Cap:
$172.51M
Revenue:
$45.07M
Net Income/Loss:
$-44.49M
P/E Ratio:
-1.6819
EPS:
-3.716
Net Cash Flow:
$-54.23M
1W Performance:
-0.16%
1M Performance:
-16.33%
6M Performance:
-0.16%
1Y Performance:
+10.04%
1-Day Range:
Value
$6.11
$6.38
1-Week Range:
Value
$5.975
$6.47
52-Week Range:
Value
$3.53
$9.62

Precision Biosciences Inc Stock (DTIL) Company Profile

Name
Name
Precision Biosciences Inc
Name
Phone
919-314-5512
Name
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Name
Employee
66
Name
Next Earnings Date
2026-11-02
Name
Latest SEC Filings
Name
DTIL's Discussions on Twitter

Compare DTIL vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
DTIL icon
DTIL
Precision Biosciences Inc
6.25 171.68M 45.07M -44.49M -54.23M -3.716
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
505.64 127.93B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
196.48 79.40B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
742.12 81.13B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
928.44 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
200.87 43.93B 742.00K -1.37B -1.07B -7.0731

Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-10-25 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-30-24 Initiated Guggenheim Buy
Jun-17-22 Initiated BMO Capital Markets Outperform
Jun-09-22 Downgrade William Blair Outperform → Mkt Perform
Jul-27-20 Resumed BTIG Research Buy
Apr-03-20 Downgrade Goldman Buy → Neutral
Mar-05-20 Initiated Stifel Buy
Feb-25-20 Initiated William Blair Outperform
Aug-09-19 Initiated BTIG Research Buy
Jul-16-19 Initiated H.C. Wainwright Buy
Apr-22-19 Initiated Barclays Overweight
Apr-22-19 Initiated Goldman Buy
Apr-22-19 Initiated JP Morgan Overweight
Apr-22-19 Initiated Jefferies Buy
View All

Precision Biosciences Inc Stock (DTIL) Latest News

pulisher
Sep 30, 2026

Director Stanley Frankel Buys 1,000 Shares of Precision BioSciences (DTIL) - GuruFocus

Sep 30, 2026
pulisher
Sep 30, 2026

At $6 per share, a director buys 1,000 Precision Biosciences (DTIL) shares - Stock Titan

Sep 30, 2026
pulisher
Sep 29, 2026

Precision BioSciences, Inc. Revenue Breakdown – HAN:PBS0 - TradingView

Sep 29, 2026
pulisher
Sep 29, 2026

Form 4 Precision BioSciences Inc For: 29 September By Investing.com - Investing.com Nigeria

Sep 29, 2026
pulisher
Sep 29, 2026

Director Melinda Brown Buys 1,135 Shares of Precision BioSciences Inc (DTIL) - GuruFocus

Sep 29, 2026
pulisher
Sep 29, 2026

Precision Biosciences director Melinda Brown buys $7,116 in stock By Investing.com - Investing.com Australia

Sep 29, 2026
pulisher
Sep 29, 2026

Precision Biosciences director Geno Germano buys $16,384 in stock - Investing.com

Sep 29, 2026
pulisher
Sep 29, 2026

Precision Biosciences director Melinda Brown buys $7,116 in stock - Investing.com

Sep 29, 2026
pulisher
Sep 29, 2026

Precision Biosciences Director Geno J. Germano Acquires 2,609 Shares at $6.28 Each - kalkinemedia.com

Sep 29, 2026
pulisher
Sep 29, 2026

At $6.27 a share, director Melinda Brown buys Precision BioSciences (DTIL) stock. - Stock Titan

Sep 29, 2026
pulisher
Sep 29, 2026

A director buys Precision BioSciences (DTIL) shares at $6.28 each, bringing his direct holdings to 47,492. - Stock Titan

Sep 29, 2026
pulisher
Sep 27, 2026

How Precision Biosciences Inc. (DTIL) Affects Rotational Strategy Timing - Stock Traders Daily

Sep 27, 2026
pulisher
Sep 24, 2026

Precision BioSciences (DTIL) Short Interest & Short Float | Updated Sep 2026 $DTIL - MarketBeat

Sep 24, 2026
pulisher
Sep 22, 2026

Precision Biosciences stock holds its Nasdaq listing - AD HOC NEWS

Sep 22, 2026
pulisher
Sep 20, 2026

Precision BioSciences, Inc.(NasdaqCM: DTIL) added to S&P Global BMI Index - marketscreener.com

Sep 20, 2026
pulisher
Sep 19, 2026

Precision BioSciences stock trades quietly amid lack of fresh catalysts - AD HOC NEWS

Sep 19, 2026
pulisher
Sep 18, 2026

Precision BioSciences Inc. (DTIL) Key Financial Ratios – Valuation, Profitability & More - Value Research

Sep 18, 2026
pulisher
Sep 17, 2026

Precision BioSciences at H.C. Wainwright conference: two shots on goal By Investing.com - Investing.com Canada

Sep 17, 2026
pulisher
Sep 11, 2026

Chronic Hepatitis B Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Thera - Barchart.com

Sep 11, 2026
pulisher
Sep 11, 2026

Precision BioSciences, Inc. Share Price Live Today – NASDAQ:DTIL Stock Price, Chart, News, History - upstox.com

Sep 11, 2026
pulisher
Sep 08, 2026

CPTx appoints Matt Kane as Chief Financial Officer - GlobeNewswire Inc.

Sep 08, 2026
pulisher
Sep 06, 2026

Behavioral Patterns of DTIL and Institutional Flows - Stock Traders Daily

Sep 06, 2026
pulisher
Sep 05, 2026

Precision BioSciences stock gains as market cap tops 200 million USD - ad-hoc-news.de

Sep 05, 2026
pulisher
Sep 05, 2026

Precision Biosciences Stock Price Forecast. Should You Buy DTIL? - StockInvest.us

Sep 05, 2026
pulisher
Sep 04, 2026

Precision BioSciences Inc. (DTIL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Sep 04, 2026
pulisher
Sep 01, 2026

Precision BioSciences Inc. (DTIL) Peer Comparison – Compare with Others - Value Research

Sep 01, 2026
pulisher
Sep 01, 2026

DTIL Q2 2026 Earnings: Wider-than-Expected Loss of $1.26 per Share Pressures StockWeak Earnings Momentum - dars.gov.et

Sep 01, 2026
pulisher
Aug 27, 2026

iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026 - Business Wire

Aug 27, 2026
pulisher
Aug 24, 2026

Precision BioSciences doses first patient in DMD gene editing trial By Investing.com - Investing.com Canada

Aug 24, 2026
pulisher
Aug 24, 2026

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study - Yahoo Finance

Aug 24, 2026
pulisher
Aug 21, 2026

Precision (DTIL) Momentum: Rises 1.61% to $8.86 in the Current Update; Chart View: the $8.42 to $9.30 Range Remains in Focus for the Current SessionGEX Level - careplusvn.com

Aug 21, 2026
pulisher
Aug 20, 2026

Precision (DTIL) Range: Posts a 2.59% Gain to $8.72 at the Close; the Current Price Sits Inside the Supplied Technical Range in the Latest ReadingLiquidity Order Flow - vinanet.vn

Aug 20, 2026
pulisher
Aug 20, 2026

DTIL Looks 355.6% Overvalued on GF Value™ - GuruFocus

Aug 20, 2026
pulisher
Aug 18, 2026

Precision BioSciences: Promising HBV Editing Evidence (NASDAQ:DTIL) - Seeking Alpha

Aug 18, 2026
pulisher
Aug 17, 2026

Precision BioSciences Inc (DTIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Aug 17, 2026
pulisher
Aug 16, 2026

Precision BioSciences Inc Stock Intrinsic Values - GuruFocus

Aug 16, 2026
pulisher
Aug 16, 2026

Precision BioSciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

Aug 16, 2026
pulisher
Aug 16, 2026

Precision BioSciences Inc (HAM:PBS0) Competitors 2026 - GuruFocus

Aug 16, 2026
pulisher
Aug 16, 2026

Precision BioSciences Inc Stock Warning Signs | HAM:PBS0 - GuruFocus

Aug 16, 2026
pulisher
Aug 16, 2026

Who's Buying or Selling Precision BioSciences Inc (HAM:PBS0) Stock Today? - GuruFocus

Aug 16, 2026
pulisher
Aug 16, 2026

Precision BioSciences Inc (HAM:PBS0) Stock Price & 30 Year Financial Data - GuruFocus

Aug 16, 2026
pulisher
Aug 16, 2026

Precision BioSciences Inc (HAM:PBS0) Stock Earnings Transcripts - GuruFocus

Aug 16, 2026
pulisher
Aug 16, 2026

Precision BioSciences Inc (HAM:PBS0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus

Aug 16, 2026
pulisher
Aug 16, 2026

HAM:PBS0 Dividend: Does Precision BioSciences Inc Pay a Dividend? - GuruFocus

Aug 16, 2026
pulisher
Aug 16, 2026

Precision BioSciences Inc (HAM:PBS0) Stock Price, Trades & News - GuruFocus

Aug 16, 2026
pulisher
Aug 16, 2026

Precision BioSciences Inc (HAM:PBS0) Stock News, Headlines & Updates - GuruFocus

Aug 16, 2026
pulisher
Aug 16, 2026

Precision BioSciences (DTIL) Rises 1.78% as Gene-Editing Stock Holds Firm Above SupportGrowth Stock Picks - vinanet.vn

Aug 16, 2026
pulisher
Aug 15, 2026

Precision BioSciences (DTIL) Advances 1.78% as Gene-Editing Speculation BuildsBear Flag - vinanet.vn

Aug 15, 2026
pulisher
Aug 13, 2026

DTIL Q2 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Quality Score - careplusvn.com

Aug 13, 2026
pulisher
Aug 11, 2026

DTIL Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Biotech ChallengesEPS Growth Report - dars.gov.et

Aug 11, 2026
pulisher
Aug 10, 2026

Analysts Have Lowered Expectations For Precision BioSciences, Inc. (NASDAQ:DTIL) After Its Latest Results - webull.com

Aug 10, 2026

Precision Biosciences Inc Stock (DTIL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Precision Biosciences Inc Stock (DTIL) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Brown Melinda
Director
Sep 25 '26
Buy
6.27
1,135
7,116
45,481
Germano Geno J
Director
Sep 25 '26
Buy
6.28
2,609
16,385
47,492
Amoroso Michael
President and CEO
Feb 17 '26
Option Exercise
0.00
67,797
0
263,951
Amoroso Michael
President and CEO
Feb 18 '26
Sale
3.84
20,559
78,947
243,392
Kelly John Alexander
Chief Financial Officer
Feb 17 '26
Option Exercise
0.00
27,584
0
134,032
Kelly John Alexander
Chief Financial Officer
Feb 18 '26
Sale
3.84
8,149
31,292
125,883
Scimeca Dario
General Counsel and Secretary
Feb 17 '26
Option Exercise
0.00
16,667
0
61,382
Scimeca Dario
General Counsel and Secretary
Feb 18 '26
Sale
3.84
4,925
18,912
56,457
SMITH J. JEFFERSON
Chief Research Officer
Feb 17 '26
Option Exercise
0.00
16,667
0
126,851
SMITH J. JEFFERSON
Chief Research Officer
Feb 18 '26
Sale
3.84
4,925
18,912
121,926
$95.25
price down icon 0.50%
$34.75
price down icon 2.20%
$56.76
price up icon 0.57%
$224.41
price up icon 0.21%
ONC ONC
$364.02
price up icon 0.34%
$200.87
price up icon 0.50%
Cap:     |  Volume (24h):